May 19, 2026—Streck has received in vitro diagnostic clearance for three MDx-Chex controls for sepsis testing. MDx-Chex for BCY, MDx-Chex for BCP, and MDx-Chex for BCN are patient-like, ready-to-use, full-process molecular quality controls designed for verification of the Diasorin Liaison Plex yeast, Gram-positive, and Gram-negative blood culture assays, respectively. The controls are supplied in 10 single-use vial kits and feature room temperature storage.
In a separate release, Streck announced the launch of its Nucleic Acid Plus BCT blood collection tube. Formerly known as Protein Plus BCT, this product has expanded its intended use claims to include cell-free DNA, cell-free RNA, extracellular vesicles, and select plasma proteins in an aim to better suit downstream multianalyte applications. Nucleic Acid Plus BCT provides stabilization of whole blood samples at ambient temperature (18°–25°C), with cfDNA and cfRNA remaining stable in stored samples for up to seven days and EVs and select plasma proteins remaining stable for up to five days. This allows for multianalyte analysis from a single draw. The tube’s proprietary preservative reagent stabilizes nucleated blood cells, red blood cells, and platelets while minimizing ex vivo hemolysis and platelet activation. Nucleic Acid Plus BCT is for research use only and available as a 5-mL configuration in packs of six, boxes of 100, or cases of 1,000. A 10-mL configuration is expected to launch later this year.